Risk stratification in localised prostate cancer: The role of genomics and AI
In this episode, UROONCO PCa associate editor Dr. Pawel Rajwa speaks with Prof. Matthew Cooperberg from the University of California about genomic and AI-based risk classifiers in localised prostate cancer and how these tools are helping to personalise patient care.
They discuss how genomic and AI classifiers complement traditional risk assessment, including PSA levels, Gleason score, and MRI findings, and how advanced risk stratification tools can help identify suitable candidates for active surveillance and guide individualised treatment strategies.
They look ahead at the future of genomics, artificial intelligence, and precision medicine in improving outcomes for men with prostate cancer.
For more updates on prostate cancer, please visit our educational platform UROONCO PCa.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.